David Calvet Canut on Takeda’s HyHub: A Shift Toward Patient-Centered Biologics
David Calvet Canut, Director TFE at UNIR, shared on LinkedIn:
“Takeda’s new HyHub™ system for HYQVIA® represents a significant advancement in patient-centered plasma-derived therapies. By simplifying subcutaneous immunoglobulin infusions, it enhances convenience and treatment adherence—areas where even small innovations can lead to meaningful improvements.
For biotech companies, this serves as a reminder that value creation now extends beyond just the molecule itself. Integration of devices, enhancement of patient experience, and home-based delivery are becoming crucial factors for competitive differentiation and securing reimbursement.
The field of plasma-derived therapies continues to evolve, and these hybrid therapy-plus-device models have the potential to redefine how we design, finance, and scale future biologics.”
Read full paper here.
Stay informed with Hemostasis Today.
-
Apr 15, 2026, 13:25Wolfgang Miesbach: Platelet Variation and How Do They Move Over Time?
-
Apr 15, 2026, 12:44Marwa Elnahas: 4Ts Scoring Tool for Heparin – Induced Thrombocytopenia
-
Apr 15, 2026, 12:27Laurent Bertoletti: Joining Global Experts to Improve Thrombosis Care in Cancer for the ICTHIC 16th Edition
-
Apr 15, 2026, 12:13Francesco Antonio Veneziano: JCDD MDPI Calls for Papers on Advances in Thrombosis and Antithrombotic Therapy
-
Apr 15, 2026, 11:05Julius Kyei Baffour: Understanding Thrombophilia Testing and Patient Risk
-
Apr 15, 2026, 09:10Shall I Bleed Less with Age? Just 2 Weeks Until the Webinar – EHC
-
Apr 15, 2026, 08:51Moustafa Abdou: Sutimlimab is Transforming Outcomes in Cold Agglutinin Disease
-
Apr 15, 2026, 04:52Ulrich Pecks: Personalized Approaches to VTE Prevention in Pregnant Women with Inherited Thrombophilia
-
Apr 15, 2026, 04:06Brenda Pleasant: Insights from the HFA Symposium on Hemophilia Care